Sterility Testing Isolators: Selection and Qualification

A sterility testing isolator should be selected and qualified around the operations the laboratory must perform: sample entry, preparation, filtration or inoculation, material transfer and handling of abnormal events. Chamber dimensions and availability of an automatic cycle are insufficient. The laboratory must demonstrate that the barrier, load, manipulations and biodecontamination support aseptic conditions without compromising test sensitivity.

Start with actual samples and sequences, translate them into testable requirements and preserve the link between requirement, risk, test and evidence. This article develops that approach through an original matrix and a simulated new-load case. Its scope is the QC laboratory, rather than an aseptic filling line or a containment isolator for hazardous substances.

1. Define intended use, load and effective capacity

Describe products, containers, quantities to handle, applicable methods and materials entering the chamber. Distinguish samples for analysis, media, filtration systems, tools and waste. For each item, record dimensions, packaging, position and transfer method. A description such as “isolator for the laboratory” does not allow verification that the planned work is feasible.

Reconstruct the complete sequence, including cleaning, loading, biodecontamination, waiting until available for use, manipulation and return to readiness. Useful capacity also depends on these steps and the transfer chamber, not merely on the number of bottles that physically fit. Compare any productivity promise against a declared load and sequence, without confusing working time with total equipment occupancy.

Check interaction with the analytical system: pump position, tubing routes, container accessibility, visibility and effluent handling. The choice between filtration and inoculation remains linked to the product and applicable compendial reference. [5] The isolator must accommodate the selected method; having it available does not automatically make a different method suitable.

2. Write configuration and ergonomic requirements

The URS should describe what the operator must be able to do, with which materials and under which conditions. Test reach, grip, container opening and identifier reading with representative gloves and accessories. An object reachable in an empty chamber may become inaccessible with the full load. Involve operators with different physical characteristics and those who will perform cleaning and maintenance.

Define glove number and position, lighting, visibility, cleanable surfaces, connections and transfer devices. Specify material compatibility with the planned treatments and component replacement arrangements. The INSST note on isolators addresses both access ergonomics and the need to start with the type of protection required. [6] Its biocontainment configurations are not a ready-made specification for your laboratory.

Identify room constraints: installation space, maintenance access, utilities, any necessary exhaust arrangements and environmental conditions. ISO 14644-7 generally covers design, construction, installation and testing of separative devices; its abstract excludes application-specific requirements. [4] Stating compliance with a general standard does not replace verification of your testing sequence.

3. Assess the barrier and its interfaces

Consider the enclosure together with gloves, sleeves, seals, doors, penetrations and connections. A pressure reading indicated as normal does not establish the integrity of every component on its own. Define which checks detect relevant leaks and how the results relate to the equipment’s use status. Assess the barrier during planned manipulations, not simply by observing idle equipment.

Identify the steps where material is introduced, waste removed or a connection changed. Specify the permitted sequence and what prevents an incorrect transfer, including door-opening conditions. A transfer device is not safe merely because of its commercial name: evidence is needed for the installed configuration and intended use.

Annex 1 addresses integrity, gloves and transfers within the framework of manufacturing barriers; for sterility testing, section 10.6 requires aseptic conditions. [1] Do not automatically transfer every environmental classification or campaign rule from a fill-finish line to the laboratory. Justify the applicable framework and supporting-room configuration with QA and competent specialists. Protecting the sample does not, by itself, demonstrate operator protection from a chemical or biological hazard.

4. Link biodecontamination, load and test sensitivity

Biodecontamination of internal surfaces and introduced materials is not equivalent to sterilising the product to be tested. If treatment reaches the sample or leaves interfering residues, it may change what the test is intended to detect. Annex 1, section 10.8, requires that external sample decontamination does not compromise method sensitivity or sample reliability. [1] The question is not only “does the cycle finish?” but also “does the test retain its meaning?”

Describe the initial cleaning state, material arrangement, exposed and shielded surfaces, absorbent materials and difficult-to-reach locations. An identified load plan, with controlled photographs or drawings, makes the configuration reproducible. The development and validation strategy should justify challenging conditions, verification locations and appropriate indicators; a chemical reading or a single indicator does not automatically describe the whole chamber.

Separate evidence of treatment effectiveness from evidence of compatibility, aeration and absence of relevant interference. Define how to establish when the system is available for use and what supporting data are needed for samples, media and materials. Avoid adopting generic concentrations or times found in a brochure. Conditions must derive from the validated configuration and applicable process; cleaning, sporicidal treatment and residue management must be consistent. [1] [5]

5. Build qualification that answers the URS

Organise the plan according to the lifecycle described in Annex 15, assigning checks and criteria before execution. [2] During design qualification, or DQ, check whether design, materials, interfaces and accessibility meet the requirements. During IQ, document installation, component identification, utilities, measuring instruments and documentation actually received. A correct nameplate does not establish that a connection is configured as intended.

OQ checks relevant functions and operating limits: controls, alarms, interlocks, interruption handling and recovery, alongside technical performance defined by the design. PQ demonstrates suitability under established use conditions, with representative loads, operators and sequences. Biodecontamination validation and demonstration of method suitability should be coordinated with these activities, while retaining the distinction between what each item of evidence demonstrates.

You may use tests performed at the supplier’s premises when they are relevant, documented and reviewed. State which results remain valid after transport and installation and which require on-site verification. A successful FAT does not authorise routine use by itself. Record deviations, their impact and release conditions; a critical issue affecting intended use does not disappear when the final report is signed.

For GMP computerised functions, coordinate access, cycle configurations, records, relevant audit trails and data recovery with the plan applicable under Annex 11. [7] Mechanical qualification alone does not establish software validation; conversely, a complete electronic record does not prove the physical effectiveness of treatment.

6. An original URS–risk–verification–evidence matrix

Use the matrix as a discussion starting point, not as an already approved protocol. Add the requirement identifier, local criterion, owner and planned phase. The checks shown are GuideGxP examples: their extent should reflect risk, use and applicable requirements.

7. Compare proposals with a common checklist

Provide candidates with the same laboratory scenario and require answers for the proposed configuration. Distinguish demonstrated performance, available options, development to be carried out and exclusions. This checklist makes visible aspects that a comparison of external dimensions alone tends to conceal.

• Does the proposed load include samples, accessories, media and waste, or only empty containers?
• Does the demonstrated sequence include transfers, cleaning, readiness after treatment and permitted activities following an abnormal event?
• Who develops and documents cycles, and who assesses interference with the method?
• Which checks are included in FAT, and which remain the site’s responsibility after installation?
• Are the configurations, data, documents and skills needed to maintain the system over time available?
• What costs and downtime are associated with consumables, gloves, maintenance, updates and load changes?

Do not automatically favour the largest chamber or the cycle advertised as fastest. A less customised proposal may work well if it meets the actual method’s needs; a sophisticated function may introduce unsustainable dependencies. Document trade-offs and who accepts any limitations.

8. Maintain the qualified state in daily use

The start-up procedure must allow the operator to recognise system status: authorised configuration, required checks completed, correct load and no impediments to use. Define glove and barrier integrity tests, inspections, transfers, monitoring and alarm handling. Establish frequencies and criteria within the applicable framework and site evidence; this article does not propose a universal schedule.

Monitoring should represent the actual environment and activities. WHO TRS 961 links sterility testing monitoring to the facility used, including an isolator, and operational conditions. [3] Monitoring results contribute to assessment of the state of control without replacing cycle effectiveness or glove integrity.

Train operators in authorised manipulations, event recognition and information to preserve. Record the session, samples, load, cycle, checks and interventions with reconstructible links. If integrity is lost or an abnormal event occurs, initiate an impact assessment for affected tests and retain the evidence. Do not assume that every positive result is attributable to the laboratory or that a negative result excludes an event’s effect.

9. Simulated case: introducing a new load

A laboratory uses an approved load with bottles in a single-level tray. For a new sample family, it proposes taller containers in a two-level holder. This case is simulated: it does not describe an experimental test or demonstrate that the arrangement is acceptable.

The first check concerns geometry and operation. Does the holder fit through the transfer chamber? Can the hands reach closures and connections without unplanned movements? Does the additional level shield surfaces, alter pathways or introduce absorbent materials? A similar total volume does not prove equivalence to the qualified load.

Open a change assessment before routine use. Compare the new load with the documented boundaries of validation: materials, arrangement, exposed surfaces and treatment conditions. Determine which evidence is transferable and what additional checks are needed for effectiveness, residues, transfer and test suitability. Do not resolve uncertainty by intuitively increasing cycle duration.

If evidence supports the configuration, update the load plan, procedures, any controlled recipes and training, with approval for return to use. If critical gaps remain, the new load is not authorised; the previous one may remain usable only if the assessment demonstrates that the change has not compromised its state. Apply the same reasoning after replacements, maintenance or software updates affecting relevant functions.

Operational conclusion

A useful dossier links laboratory work to the authorised configuration and evidence supporting its use. Keep barrier integrity, biodecontamination effectiveness and test suitability distinct: no single outcome demonstrates all three. Selection and qualification succeed when they also make limitations, responsibilities and conditions for changing the system explicit.

Continue in the Microbiology and Sterility Laboratory HUB. For method selection, see Sterility Testing: Membrane Filtration or Direct Inoculation?.

Sources and scope of application

Sources checked on 30 September 2026. The EU GMP reference here is the framework for human medicinal products; applicable texts should be checked for other scopes. ISO 14644-7:2004 remains published in the catalogue consulted, with a revision under development: the ISO/DIS draft is not treated as an adopted standard. Only the public status and abstract of the ISO text were consulted, not its full clauses. The matrix, checklist and case are GuideGxP work to be adapted locally; they do not provide cycle parameters or universal acceptance criteria.

1. European Commission — EU GMP Annex 1, Manufacture of Sterile Medicinal Products. 2022 revision, fully applicable from 25 August 2024; sections 4.18–4.23 and 10.5–10.9, distinguishing manufacturing and QC testing.
2. European Commission — EU GMP Annex 15, Qualification and Validation. 2015 revision, effective from 1 October 2015.
3. WHO — Good practices for pharmaceutical microbiology laboratories. TRS 961, Annex 2, 2011; sections 2.4, 3 and 4.
4. ISO 14644-7:2004 — Separative devices. Official catalogue, edition 1, confirmed in 2019; public scope and status.
5. WHO — The International Pharmacopoeia, 3.2 Test for sterility. Thirteenth edition, 2025; use according to the adopted compendial framework, without automatically replacing the applicable pharmacopoeia and method.
6. INSST — NTP 1203, Exposición a agentes biológicos. Equipos de seguridad: aisladores. 2024; good-practice guidance on protection from biological agents, with a scope distinct from sample sterility control.
7. European Commission — EU GMP Annex 11, Computerised Systems. January 2011 revision, for relevant GMP computerised functions.